Home The Word Brain	My Amedeo FAQ Privacy About
	C49 In our changing world, speaking just English isn't enough. Open new doors with skills in another world language. Start with 7 words a day. Next week: +49.

Influenza

Free Subscription Articles published in Antimicrob Agents Chemother Retrieve available abstracts of 29 articles: HTML format

Single Articles

April 2025
1. PANG Y, Li H, Chen X, Cao Y, et al
   A phase I, single-center, randomized, open-label, three-period crossover study to evaluate the drug-drug interaction between ZSP1273 and oseltamivir in healthy Chinese subjects.
   Antimicrob Agents Chemother. 2025;69:e0172924.
   PubMed     Abstract available
   
   
   March 2025
2. ZHAO L, Li C, Wang M, Zhou M, et al
   Potent antiviral activity of simnotrelvir against key epidemic SARS-CoV-2 variants with a high resistance barrier.
   Antimicrob Agents Chemother. 2025 Mar 10:e0155624. doi: 10.1128/aac.01556.
   PubMed     Abstract available
   
   
   February 2025
3. RODRIGUEZ L, Lee HW, Li J, Martin R, et al
   SARS-CoV-2 resistance analyses from the Phase 3 PINETREE study of remdesivir treatment in nonhospitalized participants.
   Antimicrob Agents Chemother. 2025;69:e0123824.
   PubMed     Abstract available
   
   
   December 2024
4. MENDES S, Guimaraes LC, Costa PAC, Fernandez CC, et al
   Intranasal liposomal angiotensin-(1-7) administration reduces inflammation and viral load in the lungs during SARS-CoV-2 infection in K18-hACE2 transgenic mice.
   Antimicrob Agents Chemother. 2024;68:e0083524.
   PubMed     Abstract available
   
   
   November 2024
5. ZHANG M, Lian X, Gao Y, Jiang L, et al
   LDC000067, a CDK9 inhibitor, unveils promising results in suppressing influenza virus infections in vitro and in vivo.
   Antimicrob Agents Chemother. 2024 Nov 20:e0117224. doi: 10.1128/aac.01172.
   PubMed     Abstract available
   
   
   October 2024
6. CARLIN AF, Beadle JR, Ardanuy J, Clark AE, et al
   Oral pharmacokinetics and efficacy of oral phospholipid remdesivir nucleoside prodrugs against SARS-CoV-2 in mice.
   Antimicrob Agents Chemother. 2024;68:e0103924.
   PubMed     Abstract available
   
   
   
7. MIYASHITA N, Nakamori Y, Ogata M, Fukuda N, et al
   Efficacy of ensitrelvir for cough due to COVID-19 Omicron variant in medical healthcare workers.
   Antimicrob Agents Chemother. 2024;68:e0106424.
   PubMed     Abstract available
   
   
   September 2024
8. FAGHIHI I, Yan VC
   Clinical pharmacodynamics of obeldesivir versus remdesivir.
   Antimicrob Agents Chemother. 2024;68:e0096924.
   PubMed    
   
   
   
9. POLI ANR, Tietjen I, Nandwana NK, Cassel J, et al
   Design of novel and highly selective SARS-CoV-2 main protease inhibitors.
   Antimicrob Agents Chemother. 2024 Sep 3:e0056224. doi: 10.1128/aac.00562.
   PubMed     Abstract available
   
   
   August 2024
10. FAGHIHI I, Yan VC
    Remdesivir treatment does not reduce viral titers in patients with COVID-19.
    Antimicrob Agents Chemother. 2024;68:e0085624.
    PubMed     Abstract available
    
    
    
11. SALOMEZ-IHL C, Giai J, Barbado M, Paris A, et al
    H(2) inhalation therapy in patients with moderate COVID-19 (H(2)COVID): a prospective ascending-dose phase I clinical trial.
    Antimicrob Agents Chemother. 2024;68:e0057324.
    PubMed     Abstract available
    
    
    June 2024
12. SHIN JS, Jang Y, Kim D-S, Jung E, et al
    Inhibition of endocytic uptake of severe acute respiratory syndrome coronavirus 2 and endo-lysosomal acidification by diphenoxylate.
    Antimicrob Agents Chemother. 2024;68:e0034124.
    PubMed     Abstract available
    
    
    May 2024
13. CLEGG LE, Stepanov O, Schmidt H, Tang W, et al
    Accelerating therapeutics development during a pandemic: population pharmacokinetics of the long-acting antibody combination AZD7442 (tixagevimab/cilgavimab) in the prophylaxis and treatment of COVID-19.
    Antimicrob Agents Chemother. 2024;68:e0158723.
    PubMed     Abstract available
    
    
    April 2024
14. CHESNOKOV A, Ivashchenko AA, Matsuzaki Y, Takashita E, et al
    Influenza C virus susceptibility to antivirals with different mechanisms of action.
    Antimicrob Agents Chemother. 2024 Apr 8:e0172723. doi: 10.1128/aac.01727.
    PubMed     Abstract available
    
    
    
15. XU S, Esmaeili S, Cardozo-Ojeda EF, Goyal A, et al
    Two-way pharmacodynamic modeling of drug combinations and its application to pairs of repurposed Ebola and SARS-CoV-2 agents.
    Antimicrob Agents Chemother. 2024;68:e0101523.
    PubMed     Abstract available
    
    
    
16. TANG W-F, Chang Y-H, Lin C-C, Jheng J-R, et al
    BPR3P0128, a non-nucleoside RNA-dependent RNA polymerase inhibitor, inhibits SARS-CoV-2 variants of concern and exerts synergistic antiviral activity in combination with remdesivir.
    Antimicrob Agents Chemother. 2024;68:e0095623.
    PubMed     Abstract available
    
    
    March 2024
17. YU Y, Chen S, Zhang H, Duan Y, et al
    A panel of janus kinase inhibitors identified with anti-inflammatory effects protect mice from lethal influenza virus infection.
    Antimicrob Agents Chemother. 2024 Mar 12:e0135023. doi: 10.1128/aac.01350.
    PubMed     Abstract available
    
    
    
18. MIAH M, Davis AM, Hannoun C, Said JS, et al
    Identification of epidermal growth factor receptor-tyrosine kinase inhibitor targeting the VP1 pocket of human rhinovirus.
    Antimicrob Agents Chemother. 2024;68:e0106423.
    PubMed     Abstract available
    
    
    
19. ZHANG R, Zhou J, Yan H, Liu X, et al
    Manidipine is not a potential inhibitor against SARS-CoV-2 main protease.
    Antimicrob Agents Chemother. 2024;68:e0129723.
    PubMed    
    
    
    February 2024
20. PLOTNIK D, Sager JE, Aryal M, Fanget MC, et al
    A phase 1 study in healthy volunteers to investigate the safety, tolerability, and pharmacokinetics of VIR-2482: a monoclonal antibody for the prevention of severe influenza A illness.
    Antimicrob Agents Chemother. 2024 Feb 20:e0127323. doi: 10.1128/aac.01273.
    PubMed     Abstract available
    
    
    January 2024
21. YANG H, Yu X, Hou W, Liu X, et al
    Effectiveness and safety of nirmatrelvir-ritonavir in kidney transplant recipients with severe kidney dysfunction infected with COVID-19.
    Antimicrob Agents Chemother. 2024 Jan 30:e0138423. doi: 10.1128/aac.01384.
    PubMed     Abstract available
    
    
    
22. BAKER J, Ombredane H, Daly L, Knowles I, et al
    Pan-antiviral effects of a PIKfyve inhibitor on respiratory virus infection in human nasal epithelium and mice.
    Antimicrob Agents Chemother. 2024;68:e0105023.
    PubMed     Abstract available
    
    
    
23. STRIZKI JM, Gaspar JM, Howe JA, Hutchins B, et al
    Molnupiravir maintains antiviral activity against SARS-CoV-2 variants and exhibits a high barrier to the development of resistance.
    Antimicrob Agents Chemother. 2024;68:e0095323.
    PubMed     Abstract available
    
    
    December 2023
24. ZHANG H, Zhou J, Chen H, Mao J, et al
    Phase I study, and dosing regimen selection for a pivotal COVID-19 trial of GST-HG171.
    Antimicrob Agents Chemother. 2023 Dec 15:e0111523. doi: 10.1128/aac.01115.
    PubMed     Abstract available
    
    
    November 2023
25. TONG X, Keung W, Arnold LD, Stevens LJ, et al
    Evaluation of in vitro antiviral activity of SARS-CoV-2 M(pro) inhibitor pomotrelvir and cross-resistance to nirmatrelvir resistance substitutions.
    Antimicrob Agents Chemother. 2023;67:e0084023.
    PubMed     Abstract available
    
    
    July 2023
26. PALOMINO-CABRERA R, Tejerina F, Molero-Salinas A, Ferris M, et al
    Frequent Emergence of Resistance Mutations Following Complex Intra-Host Genomic Dynamics in SARS-CoV-2 Patients Receiving Sotrovimab.
    Antimicrob Agents Chemother. 2023;67:e0026623.
    PubMed     Abstract available
    
    
    April 2023
27. DE LEON P, Canas-Arranz R, Bustos MJ, Saiz M, et al
    Inhibition of Human Coronaviruses by Combinations of Host-Targeted and Direct-Acting Antivirals.
    Antimicrob Agents Chemother. 2023;67:e0170322.
    PubMed     Abstract available
    
    
    March 2023
28. ZHANG D, Zhao Y, You X, He S, et al
    Repurposing Axl Kinase Inhibitors for the Treatment of Respiratory Syncytial Virus Infection.
    Antimicrob Agents Chemother. 2023;67:e0148722.
    PubMed     Abstract available
    
    
    
29. LIU STH, Mirceta M, Lin G, Anderson DM, et al
    Safety, Tolerability, and Pharmacokinetics of Anti-SARS-CoV-2 Immunoglobulin Intravenous (Human) Investigational Product (COVID-HIGIV) in Healthy Adults: a Randomized, Controlled, Double-Blinded, Phase 1 Study.
    Antimicrob Agents Chemother. 2023;67:e0151422.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Influenza is free of charge.